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Abstract Development of new antibiotics is declining
whereas antibiotic resistance is rising, heralding a post-
antibiotic era. Antimicrobial peptides such as gramicidin
S (GS), exclusively topically used due to its hemolytic
side-effect, could still be interesting as therapeutic com-
pounds. By modifying the amino-acid composition of
GS, we synthesized GS analogues. We now show that
derivative VK7 has a lower MIC (7.8–31.2 μg/ml, me-
dian 15.6 μg/ml) against strains of multi-drug resistant
(MDR) Klebs ie l la pneumoniae , Ac ine tobacter
baumannii, and Pseudomonas aeruginosa than GS has
(3.9–62.5 μg/ml, median 31.3 μg/ml). Low MICs for
both VK7 and GS were observed for Staphylococcus
aureus and Enterococcus faecium. VK7 showed reduced
haemolysis and less lactate dehydrogenase release. All
compounds were fully bactericidal at MIC values.
Modification of GS enables production of novel deriva-
tives potentially useful for systemic treatment of human
infections.
Introduction
Six bacterial pathogens with a propensity for developing
multi-drug resistance (MDR) are specifically warned for by
the Infectious Disease Society of America (IDSA) (ESKAPE:
Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and extended spectrum beta lactamase (ESBL)-
producing Enterobacteriaceae). These species are causing the
majority of human infections and efficiently acquire addition-
al resistance traits [1], which implies that new antibiotics have
to be effective against these actively evolving MDR patho-
gens. The incidence of vancomycin-resistant Enterococci
(VREs) has increased dramatically over recent years [2].
S. aureus, especially methicillin-resistant S. aureus (MRSA),
currently causes more deaths in the USA annually than HIV
and tuberculosis combined [2]. ESBLs continue to be on the
rise and limit treatment options [3]. P. aeruginosa is becoming
increasingly resistant to multiple classes of drugs [4], whereas
Acinetobacters are naturally resistant to many classes of anti-
biotics [5]. Increasing antibiotic resistance leads to extended
hospitalization, rising treatment costs, and increased morbid-
ity and mortality.
The rise of antibiotic-resistant pathogens has sparked re-
search into currently disregarded antimicrobial peptides in-
cluding gramicidin S (GS). GS is naturally produced by
Aneurinibacillus migulanus [6] and was first discovered in
1941 [7]. GS shows antimicrobial activity against both
Gram-positives and Gram-negatives in a MIC range from 4–
64 μg/ml [8]. The lowest MICs are seen for Gram-positive
bacterial species [9]. Despite its good antimicrobial activity,
GS cannot be used systemically due to its haemolytic side-
effect [10] and is therefore only applied topically to treat su-
perficial infections [11]. GS is a cyclic, C2-symmetrical
decapeptide with the sequence cyclo(Pro-DPhe-Leu-Orn-
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Val)2. The two Pro-
DPhe dipeptides form two type II β-turns,
and the two Leu-Orn-Val stretches form an antiparallel β-
sheet. GS has been reported to kill bacteria by forming pores
in the outer membranes [8]. Native GS is a natural scaffold for
amino acid alteration in such a way that antimicrobial activity
is retained but toxicity is reduced. In previous attempts to
modify GS, several strategies have been followed: non-
natural amino-acids were included [12], the size of the ring
has beenmodified [8], and theβ-turn region [13] andβ-strand
region have been changed [14]. Still, few new derivatives of
GS have been identified that show retention of antimicrobial
activity with reduced toxicity [8, 15–18].We here study theβ-
strand-modified GS analogue VK7 [14] and the β-turn mod-
ified derivative 20 [13]. Studying naturally occurring antimi-
crobial peptides such as GS could help with the design and
development of novel derivative drugs to combat multidrug
resistance.
Material and methods
ESKAPE panel collection and characterization Except for
the S. aureusUSA 300 and MRSA 252 strains [19], ESKAPE
strains were collected at the Department of Medical
Microbiology and Infectious Disease in the Erasmus
Medical Centre, Rotterdam, The Netherlands. Thirty clinical
isolates of E. faecium (5), S. aureus (5), K. pneumonia (5), A.
baumannii (5), P. aeruginosa (5) and E. cloacae (5) were
isolated from January 2010 to October 2011 from different
wards (Table 1). All strains were cultured on Columbia agar
plates with 5 % sheep blood (Becton Dickinson, Breda,
The Netherlands) overnight at 37 °C before antibiotic suscep-
tibility testing. Antibiotic resistance was determined using
disk diffusion following Clinical and Laboratory Standards
Institute (CLSI) guidelines and VITEK2 (bioMérieux,
Zaltbommel, The Netherlands) following manufacturer’s pro-
tocol; susceptibility was determined using EUCAST
breakpoints [20].
MIC determination Antimicrobial activity of GS and de-
rivatives (Fig. 1) was determined following the CLSI
guidelines and in triplicate [21]. Briefly, bacterial cells
were cultured overnight on Columbia agar plates with
5 % sheep b l ood (Bec t on D i ck i n son , B r ed a ,
The Netherlands). Colonies were suspended in 0.9 %
NaCl to a density of 0.5 McFarland, then diluted 1:100
in Müller–Hinton Broth (MHB, Oxoid, Badhoevedorp,
The Netherlands); 100 μl of this suspension was added
to wells containing GS, derivatives 3, 20, or VK7 ranging
from a concentration of 0.95 μg/ml to 62.5 μg/ml in
MHB. Ninety-six well plates (Greiner Bio One, Alphen
aan den Rijn, The Netherlands) were incubated for 18–24
hours at 37 °C, and MIC values were determined visually.
To determine whether antimicrobial activity was bacteri-
cidal, 200 μl of the suspension was plated onto new
Columbia agar plates with 5 % sheep blood, and colonies
were counted.
Table 1 Review of clinical isolates, their MICs to GS and derivatives,
toxicity levels, and therapeutic indices
Strain
#
3 20 GS VK-
7
Enterococcus faecium 1 7.8 15.6 3.9 3.9
2 7.8 15.6 3.9 3.9
3 7.8 7.8 3.9 3.9
4 7.8 7.8 3.9 3.9
5 7.8 3.9 3.9 3.9
Staphylococcus
aureus
1 31.3 7.8 3.9 7.8
2 7.8 3.9 3.9 3.9
3 62.5 62.5 7.8 15.6
4 31.3 7.8 3.9 7.8
5 31.2 7.8 3.9 7.8
Klebsiella
pneumoniae
1 62.5 62.5 31.3 15.6
2 31.3 62.5 62.5 15.6
3 62.5 62.5 62.5 15.6
4 31.3 62.5 31.3 15.6
5 15.6 15.6 7.8 15.6
Acinetobacter
baumannii
1 31.3 62.5 31.3 15.6
2 31.3 62.5 62.5 7.8
3 62.5 62.5 31.3 15.6
4 62.5 62.5 15.6 15.6
5 31.3 62.5 62.5 31.2
Pseudomonas
aeruginosa
1 31.3 62.5 31.3 7.8
2 31.3 31.3 31.3 7.8
3 31.3 31.3 31.3 7.8
4 62.5 62.5 62.5 7.8
5 62.5 62.5 62.5 7.8
Enterobacter
cloacae
1 3.9 7.8 3.9 7.8
2 3.9 7.8 7.8 15.6
3 7.8 7.8 3.9 7.8
4 3.9 1.95 1.95 7.8
5 62.5 62.5 62.5 15.6
Toxic dose 50 %
(hemolyse)
41.6 nd 35.2 nd
Toxic dose 50 %
(LDH)
49.8 62.5 18.7 nd
MIC lowest values 3.9 1.95 1.95 3.9
MIC highest values 62.5 62.5 62.5 31.2
TI following
hemolysis
range
0.66–
10.67
nd 0.56–
18.05
nd
TI following LDH
release
range
0.80–
12.77 1–
32.05
0.30–9.9 nd
Note: nd: not determined since the maximum concentration did not cause
toxicity.
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Haemolysis assay Haemolysis assays were performed as de-
scribed before [13]. Freshly drawn heparinised blood from
healthy volunteers was centrifuged for 10 min at 1000 g at
10 °C. The pellet was washed three times with 0.9 % saline
and diluted with saline to a 1/25 packed volume of red blood
cells. Triton-X100 (1 %) was used as a positive control. GS or
derivative 3, 20, and VK7 were diluted in 100 μl PBS in U-
bottom 96-well plates (Greiner Bio One). Serial dilution
resulted in a concentrations ranging from 62.5 μg/ml to
0.95 μg/ml. DMSO (Sigma–Aldrich, Zwijndrecht,
The Netherlands) was used as a solvent control.
Subsequently, 50 μl of the red blood cell suspension was
added to the wells, and the plates were incubated at 37 °C
for 4 h. After incubation, the plates were centrifuged at 1,
000 g at 10 °C for 4 min, and 50 μl of the supernatant of each
well was dispensed into new flat-bottom 96-well plates
(Greiner Bio One), and absorbance was measured at 415 nm
in a Bio-Rad 680 spectrophotometer (Bio-Rad, Veenendaal,
The Netherlands). OD values were plotted as a percentage of
the positive control. Experiments were performed in triplicate.
Cytotoxicity testing Human colorectal adenocarcinoma cells
(HT-29, ATCC number HTB-38, Wesel, Germany) were cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Gibco, Bleiswijk, The Netherlands) with 10 % FCS (Gibco)
and penicillin–streptomycin (Gibco). Colourless DMEM
(Gibco) with 1 % FCS (Gibco) was used as assay medium.
HT-29 cells were seeded at a density of 2.0×104 cells/well in
a Costar flat-bottom 96-well plate (Corning, Amsterdam,
The Netherlands) and incubated overnight. Serial dilutions
of GS and derivatives were added and incubated for 4 h at
37 °C. Plates were centrifuged for 10 min at 1,000 g, and the
amount of LDH in the supernatants was determined (LDH
release kit, Roche, Woerden, The Netherlands) following the
protocol. Cytotoxicity testing was independently repeated
three times.
Therapeutic indices The therapeutic index was defined as a
measure of toxicity, either the 50 % haemolysis or the 50 %
LDH release, divided by the lowest and highest MIC values
seen for each strain tested. Therapeutic indices are given as a
range to be compared between GS and its GS derivatives to
determine improved performance.
Results
Cohort collection and characterization Five strains each of
E. faecium, S. aureus, K. pneumoniae, A. baumannii, P.
aeruginosa, and E. cloacae were collected from various wards
of the Erasmus MC in 2010 and 2011 (Table 1). Extensive
antibiotic resistance was observed. S. aureus and E. faecium
showed resistances to penicillins, cephalosporins, lincosamides,
tetracyclines, macrolides, fusidic acid, aminoglycosides, carba-
penems, (fluoro)quinolones, oxazolidonones, monoxycarbolic
acid, nitrofuran derivatives, rifamycins, sulfanomides, and gly-
copeptides. Extensive drug resistance was also observed among
K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae
including aminoglycosides, (ureido)penicillins (in combination
with beta lactamase inhibitors), fluoroquinolones, polymyxins,
Fig. 1 Structure of GS and the three derivatives studied here
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carbapenems, nitrofuran derivatives, and trimethroprim with
sulfamethoxazole. Each strain showed a unique profile with
resistance to several clinically used antibiotics.
MIC determination GS was active against S. aureus and
E. faecium at 3.9–7.8 μg/ml (median 3.9 μg/ml) (Fig. 2).
MIC values against E. cloacae, P. aeruginosa, K. pneumoniae
and A. baumannii for GS ranged between 3.9–62.5 μg/ml
(median 31.3 μg/ml).
The beta-strand variant VK7 showed activity against
S. aureus and E. faecium in the range of 3.9–15.6 μg/ml (me-
dian 3.9 μg/ml), comparable to parental GS. VK7 showed
activity in the range of 7.8–31.2 μg/ml (median 15.6 μg/ml)
against E. cloacae, P. aeruginosa, K. pneumoniae, and
A. baumanii. The MIC values against all P. aeruginosa and
A. baumannii strains and most K. pneumoniae strains are 2- to
8-fold lower for VK7 than the GS MIC values.
The β-turn variant 20 showed slightly reduced activity
against S. aureus and E. faecium as compared to GS. MIC
values for compound 20 were in the range of 7.8–
62.5 μg/ml (median 7.8 μg/ml). Derivative 20 showed
activity against E. cloacae, P. aeruginosa, K. pneumoniae,
and A. baumannii in the range of 1.95–62.5 μg/ml (median
62.5 μg/ml), which is slightly less than measured for
the parental compound.
Derivative 3 showed activity against S. aureus and
E. faecium in the range from 7.8–62.5 μg/ml (median
7.8 μg/ml), which is slightly less than parental GS.
Derivative 3 shows activity against the MDR Gram-negative
strains E. cloacae, P. aeruginosa, K. pneumoniae, and
A. baumannii in the range from 3.9–62.5 μg/ml (median
31.3 μg/ml), which is comparable to the parental compound.
All compounds tested were bactericidal, as sub-culturing of
medium from wells without visible growth on agar media did
not result in detectable growth.
Haemolysis assay and therapeutic indices Haemolysis is
clearly concentration-dependant. Canonical GS showed
Fig. 2 MIC values for GS and its derivatives as defined for a collection 30 ESKAPE strains
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50 % haemolysis at 35.2 μg/ml (Fig. 3a). As the MIC values
of GS varied from 3.9 to 62.5 μg/ml, the TIhae for GS was
calculated to be between 0.56 and 18.5. Derivative 3 showed
50 % haemolysis at 41.6 μg/ml (Fig. 3a), which is in a similar
range as for the parental compound. As derivative 3 had MIC
values varying from 3.9 and 62.5 μg/ml, the TIhae of deriva-
tive 3 was calculated to be 0.6 to 10.6, also comparable to the
parental compound. This shows that derivative 3 is not an
improved antibiotic in comparison with GS. VK7 and com-
pound 20 did not show haemolysis at 62.5 μg/ml, which was
the highest concentration tested. Hence, the exact TIhae for
compound 20 and VK7 could not be determined, but still,
these derivatives are clearly less haemolytic than GS (Fig. 2).
LDH release assay and therapeutic indices The values of
50 % LDH release were 18.7 μg/ml for GS (Fig. 3b). As the
Fig. 3 Erythrocyte lysis and
LDH release under the influence
of GS and the derivatives
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MIC values were between 3.9 and 62.5 μg/ml, TILDH was
calculated to be between 0.3 and 9.6. Derivative 3 showed
50 % LDH release at 49.8 μg/ml. As the MIC values were
between 3.9 and 62.5 μg/ml, TILDH was calculated to be be-
tween 0.8 and 12.8, in the same range as documented for GS.
Derivate 20 showed 50% LDH release at 62.5μg/ml. AsMIC
values were between 1.95 and 62.5 μg/ml, TILDH was calcu-
lated to be between 1 and 32.1 μg/ml, which shows slight
improvement compared to GS. VK7 did not reach 50 %
LDH release at concentrations tested here. Therefore, no
TILDH could be calculated, indicating again that VK7 is less
cytotoxic than GS (Table 1).
Discussion
Beta-strand modification of GS seemed to be promising for
the development of new systemically applicable antibiotics.
Derivative VK7 showed activity againstE. cloacaewhichwas
equal to that of GS. Against all P. aeruginosa and
K. pneumoniae and most A. baumannii there was a 2–8-fold
increase in activity. The antimicrobial activity of VK7 against
Gram-positive MDR pathogens such as S. aureus and
E. faecium was similar to that of GS. In addition, we observed
reduced toxicity for VK7 towards human erythrocytes and the
human colorectal adenocarcinoma cell-line HT-29. The β-
strand-modified VK7 has the same overall secondary structure
as GS, but probably displays an elevated cationic character
counterbalanced by two robust hydrophobic adamantane
groups. The data indicate that β-strand modification of GS
can generate interesting new antibiotics combining anti-
microbial activity and lowered toxicity.
The β-turn-modified derivative 20 showed reduced toxic-
ity compared to the parental compound, with a slight decrease
in antibiotic activity compared to GS, especially when used
against Gram-negatives. This β-turn-modified derivative en-
compasses a substituted sugar amino acid (SAA) dipeptide
isoster as turn mimetic. The six-ring SAA in our lead was
found to have better conformational and hydrophobic charac-
teristics than a 4-ring (oxetane) and 5-ring (furanoid) SAA [9].
Beta-turn modification could still be promising, as at least
some reduction of toxic potential is observed. Not all modifi-
cations of GS have a positive effect on antimicrobial activity
and toxicity: derivative 3 shows comparable antimicrobial ac-
tivity to the parental compound but a similar toxicity profile.
The synthesis of modified GS derivatives has been reported
by other groups [8, 12, 15, 17]. One of the key factors impor-
tant in the balance between cytotoxicity and antimicrobial
activity is overall hydrophobicity–hydrophilicity. Derivatives
that are slightly less hydrophobic than the parental GS gener-
ally show good antimicrobial activity, while showing reduced
haemolysis. Using solid- and liquid-phase organic synthesis,
derivatives of GS can be obtained containing non-naturally
occurring amino acids, which show reduced cytotoxicity and
reduced haemolysis, while retaining antimicrobial activity.
Antimicrobial peptides may have a bright future in com-
bating infection, as they generally do not have a single con-
served target, but affect multiple bacterial processes.
Modifications of the β-strand of GS in which the hydrophobic
side chains have been varied are promising leads for the de-
velopment of novel compounds. New derivatives of GS can
possibly address the growing problem of multi-drug resistant
bacteria and lead to new therapeutic compounds for systemic
use, as is suggested on the basis of our current data.
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